CVS Health (NYSE:CVS) was upgraded by equities research analysts at UBS Group from an “outperform” rating to a “strong-buy” rating in a report issued on Thursday, January 4th, The Fly reports.

A number of other equities analysts have also weighed in on the stock. ValuEngine lowered shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Royal Bank of Canada initiated coverage on CVS Health in a report on Tuesday, September 19th. They issued an “outperform” rating and a $95.00 price target for the company. Jefferies Group set a $86.00 price target on CVS Health and gave the stock a “hold” rating in a report on Wednesday, October 18th. Robert W. Baird set a $77.00 price target on CVS Health and gave the stock a “hold” rating in a report on Monday, December 4th. Finally, Leerink Swann restated an “outperform” rating and issued a $85.00 price target (down previously from $90.00) on shares of CVS Health in a report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and three have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $88.06.

CVS Health (CVS) traded down $3.97 during trading hours on Thursday, hitting $79.66. 10,088,133 shares of the company were exchanged, compared to its average volume of 8,165,235. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.55. The company has a market cap of $79,720.00, a PE ratio of 16.46, a PEG ratio of 1.29 and a beta of 0.90. CVS Health has a 52 week low of $66.45 and a 52 week high of $84.00.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The company had revenue of $46.18 billion for the quarter, compared to analysts’ expectations of $46.17 billion. During the same quarter in the previous year, the firm posted $1.64 EPS. CVS Health’s revenue was up 3.5% on a year-over-year basis. sell-side analysts anticipate that CVS Health will post 5.88 EPS for the current year.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the sale, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at approximately $1,166,700. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.61% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of CVS. Horan Capital Advisors LLC. raised its position in CVS Health by 3.2% during the second quarter. Horan Capital Advisors LLC. now owns 32,115 shares of the pharmacy operator’s stock worth $2,584,000 after acquiring an additional 1,000 shares during the period. Community Bank N.A. grew its stake in shares of CVS Health by 7.3% during the second quarter. Community Bank N.A. now owns 19,976 shares of the pharmacy operator’s stock worth $1,608,000 after purchasing an additional 1,362 shares during the period. FIL Ltd grew its stake in shares of CVS Health by 13.8% during the second quarter. FIL Ltd now owns 514,836 shares of the pharmacy operator’s stock worth $41,424,000 after purchasing an additional 62,318 shares during the period. Midwest Investment Management LLC grew its stake in shares of CVS Health by 6.2% during the second quarter. Midwest Investment Management LLC now owns 21,382 shares of the pharmacy operator’s stock worth $1,720,000 after purchasing an additional 1,245 shares during the period. Finally, Fiduciary Trust Co. grew its stake in shares of CVS Health by 1.2% during the first quarter. Fiduciary Trust Co. now owns 366,007 shares of the pharmacy operator’s stock worth $28,732,000 after purchasing an additional 4,265 shares during the period. 81.64% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “CVS Health (NYSE:CVS) Upgraded by UBS Group to “Strong-Buy”” was first published by Marea Informative and is owned by of Marea Informative. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.mareainformativa.com/2018/01/30/cvs-health-cvs-lifted-to-strong-buy-at-ubs-group-updated-updated-updated.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

The Fly

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.